Ogawa Kazuhiko, Nakamura Katsumasa, Hatano Kazuo, Uno Takashi, Fuwa Nobukazu, Itami Jun, Kojya Shizuo, Nakashima Torahiko, Shinhama Akihiko, Nakagawa Takashi, Toita Takafumi, Sakai Mitsuhiro, Kodaira Takeshi, Suzuki Mikio, Ito Hisao, Murayama Sadayuki
Department of Radiology, University of the Ryukyus, Okinawa, Japan.
Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1326-34. doi: 10.1016/j.ijrobp.2007.01.052. Epub 2007 Apr 18.
To examine the relative roles of surgery, radiotherapy, and chemotherapy in the management of patients with squamous cell carcinomas of the external auditory canal and middle ear.
The records of 87 patients with histologically confirmed squamous cell carcinoma who were treated between 1984 and 2005 were reviewed. Fifty-three patients (61%) were treated with surgery and radiotherapy (S + RT group) and the remaining 34 patients with radiotherapy alone (RT group). Chemotherapy was administered in 34 patients (39%).
The 5-year actuarial overall and disease-free survival (DFS) rates for all patients were 55% and 54%, respectively. On univariate analysis, T stage (Stell's classification), treatment modality, and Karnofsky performance status had significant impact on DFS. On multivariate analysis, T stage and treatment modality were significant prognostic factors. Chemotherapy did not influence DFS. The 5-year DFS rate in T1, T2, and T3 patients was 83%, 45%, and 0 in the RT group (p < 0.0001) and 75%, 75%, and 46% in the S + RT group (p = 0.13), respectively. The 5-year DFS rate in patients with negative surgical margins, those with positive margins, and those with macroscopic residual disease was 83%, 55%, and 38%, respectively (p = 0.007).
Radical radiotherapy is the treatment of choice for early-stage (T1) diseases, whereas surgery (negative surgical margins if possible) with radiotherapy is recommended as the standard care for advanced (T2-3) disease. Further clarification on the role of chemotherapy is necessary.
探讨手术、放疗和化疗在外耳道及中耳鳞状细胞癌患者治疗中的相对作用。
回顾了1984年至2005年间接受治疗的87例经组织学确诊的鳞状细胞癌患者的记录。53例患者(61%)接受了手术和放疗(手术+放疗组),其余34例患者仅接受放疗(放疗组)。34例患者(39%)接受了化疗。
所有患者的5年精算总生存率和无病生存率(DFS)分别为55%和54%。单因素分析显示,T分期(Stell分类)、治疗方式和卡诺夫斯基功能状态对DFS有显著影响。多因素分析显示,T分期和治疗方式是显著的预后因素。化疗不影响DFS。放疗组T1、T2和T3期患者的5年DFS率分别为83%、45%和0(p<0.0001),手术+放疗组分别为75%、75%和46%(p=0.13)。手术切缘阴性、阳性和有肉眼残留病灶患者的5年DFS率分别为83%、55%和38%(p=0.007)。
根治性放疗是早期(T1)疾病的首选治疗方法,而对于晚期(T2-3)疾病,建议手术(尽可能切缘阴性)联合放疗作为标准治疗。有必要进一步明确化疗的作用。